<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02780622</url>
  </required_header>
  <id_info>
    <org_study_id>WP21272</org_study_id>
    <secondary_id>2007-005037-11</secondary_id>
    <nct_id>NCT02780622</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetics, Pharmacodynamics and Safety Study of Warfarin in Combination With Tamiflu (Oseltamivir)</brief_title>
  <official_title>An Open-label, Randomized 2-period Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Warfarin in Combination With Oseltamivir in Volunteers Stabilized on Warfarin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, 2-period crossover study, to evaluate the
      pharmacokinetics, pharmacodynamics, safety and tolerability of warfarin in combination with
      Tamiflu (oseltamivir) in participants stabilized on warfarin. Participants will be randomized
      to receive either their warfarin followed oseltamivir and warfarin, or by oseltamivir and
      warfarin followed by warfarin. The treatment periods will be separated by a washout period of
      at least 4 days. Participants will continue receiving warfarin once daily at a prescribed
      usual dose throughout the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Effect-time Curve Over 96 Hours (AUEC[0-96 h]) for International Normalized Ratio (INR)</measure>
    <time_frame>Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5)</time_frame>
    <description>INR is calculated based on results of a prothrombin time (PT) test (which measures how long it takes blood to clot) and is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin. The net AUEC(0-96 h) was calculated using the linear trapezoidal rule; this was the area under the effect-time curve and above the baseline minus the area above the curve and below the baseline during the 5-day period. An increase in INR signifies enhancement of warfarin's anticoagulant effect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Maximum Observed Effect (Emax) of International Normalized Ratio (INR)</measure>
    <time_frame>Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5)</time_frame>
    <description>INR is calculated based on results of a prothrombin time (PT) test (which measures how long it takes blood to clot) and is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin. An increase in INR signifies enhancement of warfarin's anticoagulant effect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Change From Baseline in International Normalized Ratio (INR) (Tmax)</measure>
    <time_frame>Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5)</time_frame>
    <description>INR is calculated based on results of a prothrombin time (PT) test (which measures how long it takes blood to clot) and is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin. An increase in INR signifies enhancement of warfarin's anticoagulant effect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Effect-time Curve Over 96 Hours (AUEC[0-96 h]) for Factor VII Activity</measure>
    <time_frame>Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5)</time_frame>
    <description>Factor VIIa is a protein that causes blood to clot, and low levels in the blood can cause excessive or prolonged bleeding after an injury or surgery. The net AUEC(0-96 h) was calculated using the linear trapezoidal rule; this was the area under the effect-time curve and above the baseline minus the area above the curve and below the baseline during the 5-day period. A decrease in factor VIIa activity signifies enhancement of warfarin's anticoagulant effect. kIU/L = 1000 * international units per liter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Maximum Observed Effect (Emax) in Factor VII Activity</measure>
    <time_frame>Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5)</time_frame>
    <description>Factor VIIa is a protein that causes blood to clot. A decrease in factor VIIa activity signifies enhancement of warfarin's anticoagulant effect. kIU/L = 1000 * international units per liter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Change From Baseline in Factor VII Activity (Tmax)</measure>
    <time_frame>Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5)</time_frame>
    <description>Factor VIIa is a protein that causes blood to clot. A decrease in factor VIIa activity signifies enhancement of warfarin's anticoagulant effect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Plasma Concentration of Vitamin K1</measure>
    <time_frame>Pre-dose on Day 1 and 24 hours post-dose on Day 5</time_frame>
    <description>Vitamin K1 is required by proteins involved in blood clotting. Food interaction with warfarin can lead to decreases in Vitamin K1 in plasma. An increase in vitamin K1 signifies enhancement of warfarin's anticoagulant effect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) for Oseltamivir and Oseltamivir Carboxylate</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5</time_frame>
    <description>Oseltamivir carboxylate is an active metabolite of oseltamivir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) for R- and S- Warfarin</measure>
    <time_frame>Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (t½) for Oseltamivir and Oseltamivir Carboxylate</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5</time_frame>
    <description>Oseltamivir carboxylate is an active metabolite of oseltamivir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (t½) for R- and S- Warfarin</measure>
    <time_frame>Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Plasma Clearance (CL/F) for Oseltamivir</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Plasma Clearance (CL/F) for R- and S- Warfarin</measure>
    <time_frame>Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) for Oseltamivir and Oseltamivir Carboxylate</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) for R- and S- Warfarin</measure>
    <time_frame>Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5</time_frame>
    <description>R- and S-warfarin are two molecular versions of warfarin with slightly different structures. The reported concentrations were normalized by dividing the Cmax values (nanograms per milliliter) by the individual average dose (milligrams).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 24 Hours (AUC0-24h) for Oseltamivir and Oseltamivir Carboxylate</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18 and 24 hours post-dose on Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 24 Hours (AUC0-24h) for R- and S- Warfarin</measure>
    <time_frame>Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5</time_frame>
    <description>R- and S-warfarin are two molecular versions of warfarin with slightly different structures. The reported concentrations were normalized by dividing the AUC values (hours multiplied by nanograms, per milliliter) by the individual average dose (milligrams).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 12 Hours (AUC0-12h) for Oseltamivir and Oseltamivir Carboxylate</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 12 Hours (AUC0-12h) for R- and S- Warfarin</measure>
    <time_frame>Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5</time_frame>
    <description>R- and S-warfarin are two molecular versions of warfarin with slightly different structures. The reported concentrations were normalized by dividing the AUC values (hours multiplied by nanograms, per milliliter) by the individual average dose (milligrams).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Up to Day 26</time_frame>
    <description>An adverse event was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Drug Therapy, Combination</condition>
  <arm_group>
    <arm_group_label>First Warfarin Then Warfarin and Oseltamivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive warfarin (on Days 1-5) in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive oseltamivir 75 milligram (mg) (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First Warfarin and Oseltamivir Then Warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oseltamivir 75 mg (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive warfarin (on Days 1-5) in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>Oseltamivir 75 mg orally, twice daily for 4 days and once on Day 5.</description>
    <arm_group_label>First Warfarin Then Warfarin and Oseltamivir</arm_group_label>
    <arm_group_label>First Warfarin and Oseltamivir Then Warfarin</arm_group_label>
    <other_name>Tamiflu®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin once daily, at a dose determined through titration by participants' usual hematologist.</description>
    <arm_group_label>First Warfarin Then Warfarin and Oseltamivir</arm_group_label>
    <arm_group_label>First Warfarin and Oseltamivir Then Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have been receiving warfarin once daily for at least 4 weeks prior
             to Screening

          -  Participants must have regular International Normalized ratio (INR) monitoring during
             warfarin therapy prior to study entry, and be willing to be trained in the use of
             CoaguCheck devices

          -  INR must fall within a target range of 2.0-3.5

          -  Body mass index (BMI) between 18-32 kg/m^2 inclusive

        Exclusion Criteria:

          -  An INR value between screening and Day -1 lower than 2.0 or greater than 3.5

          -  A change in prescribed daily warfarin dose between Screening and Day -1

          -  History of any coagulopathy

          -  Consumption of health products or supplements containing vitamin K

          -  Pregnant or lactating women

          -  Confirmed positive urine and/or blood test for drugs of abuse at Screening or Day -1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Surrey</city>
        <zip>CR7 7YE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2016</study_first_posted>
  <results_first_submitted>July 25, 2016</results_first_submitted>
  <results_first_submitted_qc>July 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2016</results_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>First Warfarin Then Warfarin and Oseltamivir</title>
          <description>Participants received warfarin (on Days 1-5) in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants then received oseltamivir 75 milligram (mg) (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 2, and attended a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants continued to receive warfarin once daily at a prescribed usual dose throughout the study.</description>
        </group>
        <group group_id="P2">
          <title>First Warfarin and Oseltamivir Then Warfarin</title>
          <description>Participants received oseltamivir 75 mg (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants then received warfarin (on Days 1-5) in Treatment Period 2, and attended a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants continued to receive warfarin once daily at a prescribed usual dose throughout the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed on all enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Participants were randomized to 1 of 2 treatment sequences: warfarin then oseltamivir 75 mg and warfarin; or oseltamivir 75 mg and warfarin then warfarin.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Effect-time Curve Over 96 Hours (AUEC[0-96 h]) for International Normalized Ratio (INR)</title>
        <description>INR is calculated based on results of a prothrombin time (PT) test (which measures how long it takes blood to clot) and is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin. The net AUEC(0-96 h) was calculated using the linear trapezoidal rule; this was the area under the effect-time curve and above the baseline minus the area above the curve and below the baseline during the 5-day period. An increase in INR signifies enhancement of warfarin’s anticoagulant effect.</description>
        <time_frame>Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5)</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Effect-time Curve Over 96 Hours (AUEC[0-96 h]) for International Normalized Ratio (INR)</title>
          <description>INR is calculated based on results of a prothrombin time (PT) test (which measures how long it takes blood to clot) and is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin. The net AUEC(0-96 h) was calculated using the linear trapezoidal rule; this was the area under the effect-time curve and above the baseline minus the area above the curve and below the baseline during the 5-day period. An increase in INR signifies enhancement of warfarin’s anticoagulant effect.</description>
          <population>All enrolled participants.</population>
          <units>hours*ratio</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" lower_limit="-27.6" upper_limit="78.0"/>
                    <measurement group_id="O2" value="-9.06" lower_limit="-93.6" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Maximum Observed Effect (Emax) of International Normalized Ratio (INR)</title>
        <description>INR is calculated based on results of a prothrombin time (PT) test (which measures how long it takes blood to clot) and is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin. An increase in INR signifies enhancement of warfarin’s anticoagulant effect.</description>
        <time_frame>Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5)</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Maximum Observed Effect (Emax) of International Normalized Ratio (INR)</title>
          <description>INR is calculated based on results of a prothrombin time (PT) test (which measures how long it takes blood to clot) and is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin. An increase in INR signifies enhancement of warfarin’s anticoagulant effect.</description>
          <population>All enrolled participants.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="2.1"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Change From Baseline in International Normalized Ratio (INR) (Tmax)</title>
        <description>INR is calculated based on results of a prothrombin time (PT) test (which measures how long it takes blood to clot) and is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin. An increase in INR signifies enhancement of warfarin's anticoagulant effect.</description>
        <time_frame>Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5)</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Change From Baseline in International Normalized Ratio (INR) (Tmax)</title>
          <description>INR is calculated based on results of a prothrombin time (PT) test (which measures how long it takes blood to clot) and is used to monitor individuals who are being treated with the blood-thinning medication (anticoagulant) warfarin. An increase in INR signifies enhancement of warfarin's anticoagulant effect.</description>
          <population>All enrolled participants.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.00" lower_limit="0.00" upper_limit="96.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="96.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Effect-time Curve Over 96 Hours (AUEC[0-96 h]) for Factor VII Activity</title>
        <description>Factor VIIa is a protein that causes blood to clot, and low levels in the blood can cause excessive or prolonged bleeding after an injury or surgery. The net AUEC(0-96 h) was calculated using the linear trapezoidal rule; this was the area under the effect-time curve and above the baseline minus the area above the curve and below the baseline during the 5-day period. A decrease in factor VIIa activity signifies enhancement of warfarin's anticoagulant effect. kIU/L = 1000 * international units per liter.</description>
        <time_frame>Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5)</time_frame>
        <population>All enrolled participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Effect-time Curve Over 96 Hours (AUEC[0-96 h]) for Factor VII Activity</title>
          <description>Factor VIIa is a protein that causes blood to clot, and low levels in the blood can cause excessive or prolonged bleeding after an injury or surgery. The net AUEC(0-96 h) was calculated using the linear trapezoidal rule; this was the area under the effect-time curve and above the baseline minus the area above the curve and below the baseline during the 5-day period. A decrease in factor VIIa activity signifies enhancement of warfarin's anticoagulant effect. kIU/L = 1000 * international units per liter.</description>
          <population>All enrolled participants with available data.</population>
          <units>hours*kIU/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.568" lower_limit="-9.48" upper_limit="7.56"/>
                    <measurement group_id="O2" value="1.45" lower_limit="-5.16" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Maximum Observed Effect (Emax) in Factor VII Activity</title>
        <description>Factor VIIa is a protein that causes blood to clot. A decrease in factor VIIa activity signifies enhancement of warfarin's anticoagulant effect. kIU/L = 1000 * international units per liter.</description>
        <time_frame>Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5)</time_frame>
        <population>All enrolled participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Maximum Observed Effect (Emax) in Factor VII Activity</title>
          <description>Factor VIIa is a protein that causes blood to clot. A decrease in factor VIIa activity signifies enhancement of warfarin's anticoagulant effect. kIU/L = 1000 * international units per liter.</description>
          <population>All enrolled participants with available data.</population>
          <units>kIU/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0505" lower_limit="-0.21" upper_limit="0.00"/>
                    <measurement group_id="O2" value="-0.0432" lower_limit="-0.15" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Change From Baseline in Factor VII Activity (Tmax)</title>
        <description>Factor VIIa is a protein that causes blood to clot. A decrease in factor VIIa activity signifies enhancement of warfarin's anticoagulant effect.</description>
        <time_frame>Pre-dose on Day 1, 24 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), and 96 hours (Day 5)</time_frame>
        <population>All enrolled participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Change From Baseline in Factor VII Activity (Tmax)</title>
          <description>Factor VIIa is a protein that causes blood to clot. A decrease in factor VIIa activity signifies enhancement of warfarin's anticoagulant effect.</description>
          <population>All enrolled participants with available data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.00" lower_limit="0.00" upper_limit="96.00"/>
                    <measurement group_id="O2" value="72.00" lower_limit="0.00" upper_limit="96.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Plasma Concentration of Vitamin K1</title>
        <description>Vitamin K1 is required by proteins involved in blood clotting. Food interaction with warfarin can lead to decreases in Vitamin K1 in plasma. An increase in vitamin K1 signifies enhancement of warfarin's anticoagulant effect.</description>
        <time_frame>Pre-dose on Day 1 and 24 hours post-dose on Day 5</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Concentration of Vitamin K1</title>
          <description>Vitamin K1 is required by proteins involved in blood clotting. Food interaction with warfarin can lead to decreases in Vitamin K1 in plasma. An increase in vitamin K1 signifies enhancement of warfarin's anticoagulant effect.</description>
          <population>All enrolled participants.</population>
          <units>nanogram per liter (ng/L)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305" lower_limit="-371" upper_limit="1060"/>
                    <measurement group_id="O2" value="271" lower_limit="-1100" upper_limit="1310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) for Oseltamivir and Oseltamivir Carboxylate</title>
        <description>Oseltamivir carboxylate is an active metabolite of oseltamivir.</description>
        <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) for Oseltamivir and Oseltamivir Carboxylate</title>
          <description>Oseltamivir carboxylate is an active metabolite of oseltamivir.</description>
          <population>All enrolled participants.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir (Single Dose: Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.50" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir Carboxylate (Single Dose: Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir (Steady State: Day 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.50" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir Carboxylate (Steady State: Day 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="3.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) for R- and S- Warfarin</title>
        <time_frame>Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) for R- and S- Warfarin</title>
          <population>All enrolled participants.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total (S)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="8.13"/>
                    <measurement group_id="O2" value="4.00" lower_limit="0.00" upper_limit="23.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free (S)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="8.74" upper_limit="53.8"/>
                    <measurement group_id="O2" value="3.01" lower_limit="1.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total (R)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="1.00" upper_limit="11.83"/>
                    <measurement group_id="O2" value="4.00" lower_limit="1.00" upper_limit="23.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free (R)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="1.00" upper_limit="11.83"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.00" upper_limit="11.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (t½) for Oseltamivir and Oseltamivir Carboxylate</title>
        <description>Oseltamivir carboxylate is an active metabolite of oseltamivir.</description>
        <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t½) for Oseltamivir and Oseltamivir Carboxylate</title>
          <description>Oseltamivir carboxylate is an active metabolite of oseltamivir.</description>
          <population>All enrolled participants.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir (Single Dose: Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir Carboxylate (Single Dose: Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.17" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir (Steady State: Day 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir Carboxylate (Steady State: Day 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.19" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (t½) for R- and S- Warfarin</title>
        <time_frame>Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t½) for R- and S- Warfarin</title>
          <population>All enrolled participants.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total (S)-warfarin (n = 13, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4" spread="23.0"/>
                    <measurement group_id="O2" value="45.6" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total (R)-warfarin (n = 12, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="26.1"/>
                    <measurement group_id="O2" value="53.6" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Plasma Clearance (CL/F) for Oseltamivir</title>
        <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Plasma Clearance (CL/F) for Oseltamivir</title>
          <population>All enrolled participants.</population>
          <units>liters per hour (L/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir (Single Dose: Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="558" spread="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir (Steady State: Day 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463" spread="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Plasma Clearance (CL/F) for R- and S- Warfarin</title>
        <time_frame>Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Plasma Clearance (CL/F) for R- and S- Warfarin</title>
          <population>All enrolled participants.</population>
          <units>liters per hour (L/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total (S)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.198" spread="0.0895"/>
                    <measurement group_id="O2" value="0.208" spread="0.0959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free (S)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" spread="17"/>
                    <measurement group_id="O2" value="38.2" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total (R)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.139" spread="0.0361"/>
                    <measurement group_id="O2" value="0.145" spread="0.0374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free (R)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" spread="5.74"/>
                    <measurement group_id="O2" value="22" spread="5.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) for Oseltamivir and Oseltamivir Carboxylate</title>
        <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) for Oseltamivir and Oseltamivir Carboxylate</title>
          <population>All enrolled participants.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir (Single Dose: Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" spread="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir Carboxylate (Single Dose: Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367" spread="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir (Steady State: Day 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" spread="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir Carboxylate (Steady State: Day 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="571" spread="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) for R- and S- Warfarin</title>
        <description>R- and S-warfarin are two molecular versions of warfarin with slightly different structures. The reported concentrations were normalized by dividing the Cmax values (nanograms per milliliter) by the individual average dose (milligrams).</description>
        <time_frame>Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) for R- and S- Warfarin</title>
          <description>R- and S-warfarin are two molecular versions of warfarin with slightly different structures. The reported concentrations were normalized by dividing the Cmax values (nanograms per milliliter) by the individual average dose (milligrams).</description>
          <population>All enrolled participants.</population>
          <units>Nanogram/milliliter/milligram (ng/mL/mg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total (S)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="394" spread="259"/>
                    <measurement group_id="O2" value="330" spread="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free (S)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="1.30"/>
                    <measurement group_id="O2" value="1.68" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total (R)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436" spread="243"/>
                    <measurement group_id="O2" value="375" spread="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free (R)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="1.45"/>
                    <measurement group_id="O2" value="2.37" spread="0.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 24 Hours (AUC0-24h) for Oseltamivir and Oseltamivir Carboxylate</title>
        <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18 and 24 hours post-dose on Day 5</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 24 Hours (AUC0-24h) for Oseltamivir and Oseltamivir Carboxylate</title>
          <population>All enrolled participants.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir (Steady state: Day 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176" spread="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir Carboxylate (Steady State: Day 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7180" spread="2550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 24 Hours (AUC0-24h) for R- and S- Warfarin</title>
        <description>R- and S-warfarin are two molecular versions of warfarin with slightly different structures. The reported concentrations were normalized by dividing the AUC values (hours multiplied by nanograms, per milliliter) by the individual average dose (milligrams).</description>
        <time_frame>Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 24 Hours (AUC0-24h) for R- and S- Warfarin</title>
          <description>R- and S-warfarin are two molecular versions of warfarin with slightly different structures. The reported concentrations were normalized by dividing the AUC values (hours multiplied by nanograms, per milliliter) by the individual average dose (milligrams).</description>
          <population>All enrolled participants.</population>
          <units>h*ng/mL/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total (S)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6770" spread="4500"/>
                    <measurement group_id="O2" value="6460" spread="4310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free (S)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2" spread="26.1"/>
                    <measurement group_id="O2" value="33.9" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total (R)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7790" spread="2480"/>
                    <measurement group_id="O2" value="7360" spread="1960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free (R)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" spread="13.4"/>
                    <measurement group_id="O2" value="48.3" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 12 Hours (AUC0-12h) for Oseltamivir and Oseltamivir Carboxylate</title>
        <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 1 and 5; 18 and 24 hours post-dose on Day 5</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 12 Hours (AUC0-12h) for Oseltamivir and Oseltamivir Carboxylate</title>
          <population>All enrolled participants.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir (Single Dose: Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141" spread="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir Carboxylate (Single Dose: Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2990" spread="793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir (Steady State: Day 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169" spread="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir Carboxylate (Steady State: Day 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5110" spread="1630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 12 Hours (AUC0-12h) for R- and S- Warfarin</title>
        <description>R- and S-warfarin are two molecular versions of warfarin with slightly different structures. The reported concentrations were normalized by dividing the AUC values (hours multiplied by nanograms, per milliliter) by the individual average dose (milligrams).</description>
        <time_frame>Pre-dose; 1, 2, 4, 8, 12, 24 hours post-dose on Day 5</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to 12 Hours (AUC0-12h) for R- and S- Warfarin</title>
          <description>R- and S-warfarin are two molecular versions of warfarin with slightly different structures. The reported concentrations were normalized by dividing the AUC values (hours multiplied by nanograms, per milliliter) by the individual average dose (milligrams).</description>
          <population>All enrolled participants.</population>
          <units>h*ng/mL/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total (S)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3610" spread="2200"/>
                    <measurement group_id="O2" value="3380" spread="2100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free (S)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" spread="13.0"/>
                    <measurement group_id="O2" value="17.8" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total (R)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4140" spread="1320"/>
                    <measurement group_id="O2" value="3870" spread="1020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free (R)-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" spread="7.84"/>
                    <measurement group_id="O2" value="24.8" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events</title>
        <description>An adverse event was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>Up to Day 26</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin and Oseltamivir</title>
            <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events</title>
          <description>An adverse event was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
          <population>All enrolled participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Five days for each treatment period (Up to Day 26)</time_frame>
      <desc>All enrolled participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Warfarin</title>
          <description>Participants who received Warfarin alone at a prescribed usual dose in treatment period 1 or treatment period 2.</description>
        </group>
        <group group_id="E2">
          <title>Warfarin and Oseltamivir</title>
          <description>Participants who received warfarin at a prescribed usual dose along with oseltamivir 75 mg, orally twice daily on Days 1-4 and once on Day 5 in treatment period 1 or treatment period 2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Venipuncture site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

